Christopher U. Jones

Sutter Medical Center — United States

Medicine · Health Sciences

37h-index16.9kcitations118works2.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Head and Neck Cancer Studies(63), Lung Cancer Treatments and Mutations(32), Prostate Cancer Treatment and Research(25), Prostate Cancer Diagnosis and Treatment(23), Advanced Radiotherapy Techniques(20)

Publications118 total

Treatment Interruption and Outcomes in Head and Neck Cancer
JAMA Otolaryngology–Head & Neck Surgery·2025Open Access
1326MO RTOG 1016 long-term update and smoking analysis
Annals of Oncology·2025
Self-Perceived Hearing Outcomes With Radiation and Cisplatin or Radiation and Cetuximab for Patients With Human Papilloma Virus (HPV)-Positive Oropharyngeal Cancer—Results From NRG Oncology RTOG 1016
International Journal of Radiation Oncology*Biology*Physics·2025
Long-Term Feeding Tube Use in Head and Neck Cancer Survivors—An Analysis of Patient- and Treatment-Related Factors
International Journal of Radiation Oncology*Biology*Physics·2025· 1 citedOpen Access
Supplementary Table S4 from Association between Locoregional Failure and <i>NFE2L2/KEAP1/CUL3</i> Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer
2025Open Access
Supplementary Table S6 from Association between Locoregional Failure and <i>NFE2L2/KEAP1/CUL3</i> Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer
2025Open Access
Data from Association between Locoregional Failure and <i>NFE2L2/KEAP1/CUL3</i> Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer
2025Open Access
Supplementary Table S2 from Association between Locoregional Failure and <i>NFE2L2/KEAP1/CUL3</i> Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer
2025Open Access
Supplementary Figure S1 from Association between Locoregional Failure and <i>NFE2L2/KEAP1/CUL3</i> Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer
2025Open Access
Supplementary Table S9 from Association between Locoregional Failure and <i>NFE2L2/KEAP1/CUL3</i> Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer
2025Open Access
Supplementary Table S5 from Association between Locoregional Failure and <i>NFE2L2/KEAP1/CUL3</i> Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer
2025Open Access
Supplementary Figure S2 from Association between Locoregional Failure and <i>NFE2L2/KEAP1/CUL3</i> Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer
2025Open Access
Supplementary Table S7 from Association between Locoregional Failure and <i>NFE2L2/KEAP1/CUL3</i> Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer
2025Open Access
Supplementary Table S3 from Association between Locoregional Failure and <i>NFE2L2/KEAP1/CUL3</i> Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer
2025Open Access
Supplementary Table S8 from Association between Locoregional Failure and <i>NFE2L2/KEAP1/CUL3</i> Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer
2025Open Access
Supplementary Table S1 from Association between Locoregional Failure and <i>NFE2L2/KEAP1/CUL3</i> Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer
2025Open Access
Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer
Journal of Clinical Oncology·2025· 8 cited
Association between Locoregional Failure and <i>NFE2L2/KEAP1/CUL3</i> Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer
Clinical Cancer Research·2024· 5 citedOpen Access
Corrigendum to “Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostat Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial” [Eur. Eurol. 84(2) (2023) 156–163]
European Urology·2024
Surrogate Endpoints in p16-Positive Squamous Cell Carcinoma of the Oropharynx
International Journal of Radiation Oncology*Biology*Physics·2024
page 1 of 6Next →

Frequent Co-authors

Adam S. Garden(13), Andy Trotti(11), Jonathan Harris(11), Quynh‐Thu Le(11), Howard M. Sandler(10), John A. Ridge(9), William U. Shipley(8), Paul M. Harari(7), Jeff M. Michalski(7), Randal S. Weber(7), James A. Bonner(6), David Raben(6), Sharon A. Spencer(6), Min Yao(6), Deborah Watkins Bruner(6), Luís Souhami(6), Mack Roach(6), Sue S. Yom(6), Kenneth L. Zeitzer(6), Elizabeth Gore(6)